Suven Life Sciences Limited
1989 Incorporation as Suven Pharmaceuticals Pvt. Ltd.
1990 Commenced Operations
1991 Expanded into Fine Chemical Intermediates
1992 Commenced export of Fine Chemical Intermediates
1994 Initiation of 'C-R-A-M-S' business model (Contract Research And Manufacturing Services)
1995 Went Public (IPO)
1996 First sale from 'C-R-A-M-S'
1997 ISO 9002 Certification
1999 Recognition as an Export House
1999 Acquired a Drug Unit at Hyderabad, converted into Research center and Pilot Plant
2001 New Suven Research Center (SRC) inaugurated at Hyderabad
2001 Recognition of SRC as in-house R & D unit by Department of Scientific & Industrial Research (DSIR), India
2001 Borregaard takes equity stake
2002 cGMP Lab at SRC commissioned
2003 Acquired assets of New Jersey, USA based Synthon Chiragenics Corporation
2003 Name changed to Suven Life Sciences Limited
2004 Gets ISO 14001:1996 certification for Unit - 1 (Suryapet) and Unit - 2 (Jeedimetla)
2005 Suven Awarded 2005 - Partner of Choice in Drug Discovery for CNS by Frost & Sullivan
2005 Suven Awarded Phase III Clinical study for Chronic Low Back pain.
2006 Suven receives National Accreditation Board for Testing and Calibration Laboratories (NABL) certification
2006 Suven and Lilly Establish Drug Discovery Collaboration
2006 All the units got Certification for  ISO 9001 , ISO 14001, OHSAS 18001
2007 Suven Unit III cGMP facility accepted by USFDA for manufacture of API's
2007 Suven enters into collaboration with University of Minnesota to develop drugs to treat HIV infection
2007 Suven obtains 1st Product Patent from US Patent office
2008 Suven Establishes second CNS Drug Discovery Collaboration with Lilly
2008 Suven granted Certificate of Suitability (CEP) for Tamsulosin Hydrochloride
2009 Suven participation at Biotech Showcase 2009.
2009 SUVEN’S UNIT- I RECEIVES US FDA ACCEPTANCE.
2009 Suven achieves 1st Milestone payment in Drug Discovery collaboration
2010 Suven’s partnering and fundraising activity at C21 BioVentures™
2010 Suven Life Sciences presenting at International Conference on Alzheimer’s Disease (ICAD)
2010 Suven Life Sciences bags Pharmexcil's Gold “Patent Award
2011 Suven’s partnering and fund-raising activity at J.P. Morgan Healthcare Conference 2011
2011 Suven Life Sciences bags “Bio-Excellence Award at Bangalore India Bio 2011”
2011 Suven Participating at 4th CNS Partnering & Deal Making Conference in USA
2011 Suven Life Sciences bags Pharmexcil’s Gold “Patent Award
2012 Suven to Present at Alzheimer's Association International Conference (AAIC)
2012 Suven Life Sciences bags Pharmexcil’s “Platinum Patent Award”
2014 SUVEN’S PASHAMYLARAM’S UNIT RECEIVES US FDA ACCEPTANCE
2014 Suven Life Sciences bags Pharmexcil’s “Gold Patent Award” for NCE’s and “Outstanding Export Performance Award” for Contract Research and Manufacturing.
2014 Suven Life Sciences awarded Forbes Asia's "Best Under A Billion" Award
2015 Suven Life Sciences bags Pharmexcil's "Gold Patent Award"
2015 SUVN 502- Completed phase 1b clinical trial under US-IND;
2015 SUVN-G3031- Completed SAD and MAD studies of phase 1 clinical trial under US-IND
2015 SUVN-D4010 IND filed in USA
2015 Suven facility at JNPC, Vishakapatnam, Andhra Pradesh has commenced commercial operations
2015 SUVN-D4010 for Cognition in Alzheimer’s disease commenced Phase 1 Clinical Trial in USA under US-IND126099
2015 Suven has created a wholly owned subsidiary, Suven, Inc., a Delaware Company in USA
2015 Suven initiates Phase 2A trial of SUVN-502 in USA
2016 SUVN-D4010 Phase 1 clinical trial completed successfully in USA.
2016 Suven’s Pashamylaram unit successfully completed US FDA inspection
2017 Suven Life sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a nAChRs antagonist for MDD